**Supplementary Figure Legends**

**Supplementary Figure 1. Body weights of rats treated with OH-BBN and erlotinib and/or naproxen. A.** Body weight graph of rats receiving erlotinib and/or naproxen one week post final carcinogen treatment during the chemoprevention study. **B.** Body weight graph of rats receiving erlotinib and/or naproxen three months post final carcinogen treatment during the chemoprevention study. C. Body weight graph of rats receiving erlotinib and/or naproxen one month post final carcinogen treatment during the chemoprevention study.

**Supplementary Figure 2. Effect of erlotinib and/or naproxen on biomarker expressions.** Expression of cell proliferation (ki67) **(A)**, pSTAT3 **(B),** pP38 **(C)**, Cyclin D1 **(D),** pERK **(E),** and IL1β **(F)** in urinary bladder transitional cell cancers induced in female fischer-344 rats with hydroxy butyl (butyl) nitrosamine